Affiliation:
1. 1 (Corresponding author) Assistant Clinical Professor, University of Connecticut, Storrs, Connecticut, kristin.waters@uconn.edu
Abstract
Abstract
Whereas MDD is characterized in part by changes in mood, other symptoms can also cause significant impairment, including sexual dysfunction, cognitive impairment, and fatigue. Newer antidepressants are explored with the goal of more optimally treating these non–mood-related symptoms of MDD. The 3 oral antidepressants that have been FDA-approved most recently include vortioxetine, vilazodone, and levomilnacipran. Unique features of these antidepressants are explored through 3 patient cases.
Publisher
College of Psychiatric and Neurologic Pharmacists (CPNP)
Subject
Pharmacology (medical),Neurology (clinical),General Pharmacology, Toxicology and Pharmaceutics,Neuropsychology and Physiological Psychology
Reference86 articles.
1. National Institute of Mental Health [Internet].
Major depression;
2017
[cited 2022 Jul].
Available from: https://www.nimh.nih.gov/health/statistics/major-depression
2. American Psychiatric Association.
Diagnostic and Statistical Manual of Mental Disorders. 5th ed.
Washington:
American Psychiatric Association;2013.
3. Greenberg
PE,
Fournier
A-A,
Sisitsky
T,
Pike
CT,
Kessler
RC.
The economic burden of adults with major depressive disorder in the United States (2005 and 2010).
J Clin Psychiatry.
2015;
76(2):
155-
62.
DOI: 10.4088/JCP.14m09298. PubMed PMID: 25742202.
4. Zhdanava
M,
Pilon
D,
Ghelerter
I,
Chow
W,
Joshi
K,
Lefebvre
P,
et al.
The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States.
J Clin Psychiatry.
2021;
82(2):20m13699.DOI: 10.4088/JCP.20m13699. PubMed PMID: 33989464.
5. Pratt
LA,
Brody
DJ,
Gu
Q.
Antidepressant use among persons aged 12 and over: United States, 2011-2014.
NCHS Data Brief.
2017;
(283):
1-
8.
PubMed PMID: 29155679.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献